A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Paraganglioma; Pheochromocytoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 22 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 01 Apr 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.